Corporate News

DreamCIS received Korea “2020 National Industry Award”June 5, 2020DreamCIS (stock code: A223250), a subsidiary of Tigermed, and a leading Korea-based contract research organization (CRO) providing comprehensive R&D services to biopharmaceutical...

Tigermed Receives 2020 Chinese Contract Research Organizations Customer Value Leadership Award from Frost & SullivanJune 2, 2020HANGZHOU, China, June 2, 2020 -- Tigermed, a leading Contract Research Organization (CRO) in China dedicated to provide full...

DreamCIS is Successfully Landed on Korea Stock ExchangeMay 22, 2020SEOUL, HANGZHOU, May 22, 2020 – DreamCIS (stock code: A223250), a Tigermed company, and a contract research organization (CRO) providing comprehensive R&D services to biopharmaceutical...

A brand new start for Tigermed with new official website and new email domain!May 8, 2020After several months of work and dedication, we are thrilled to officially announce that Tigermed new website is now Live! We invite you to visit us...

Top Medical Journal “The Lancet” Publishes Results of First Randomized Controlled Clinical Trial of Remdesivir, which was fully supported by TigermedApril 30, 2020April 29, 2020, the international medical journal The Lancet published online the results of...

Tigermed Releases 2019 Annual Report with Solid Financial Results April 16, 2020   April 16, 2020 -- Hangzhou Tigermed Consulting Co., Ltd (stock code: 300347), a contract research organization (CRO) dedicated to providing full comprehensive services...

Tigermed and Accerise Announce Joint VentureNovember 27, 2019Hangzhou Tigermed Consulting Co., Ltd. (hereinafter referred to as "Tigermed") and Accerise Inc. (hereinafter referred to as "Accerise") jointly announced to establish a joint venture on January...

Tigermed Releases Its 2019 Half-yearly Report, with Year On Year Net Profit Up 61.03%August 29, 2019Tigermed (Chinese Stock code: 300347), a company that aims to provide full services for clinical research which enable companies in the pharmaceutical,...

Tigermed and AstraZeneca (China) Announced a Strategic Partnership, a Joint Acceleration of Drug Research and DevelopmentJuly 10, 2019On July 5, 2019, Tigermed and AstraZeneca (China) signed a strategic cooperation agreement in Shanghai, China, announcing...

Frontage Holdings Corporation Won Warm Market Response on First Trading Day Closed at HK$3.35, up 4.69% vs Offer PriceJune 4, 2019Frontage Holdings Corporation方達控股公司 * (Incorporated in the Cayman Islands with limited liability)(Stock code: 1521)(May 31,...

Tigermed Releases 2018 Annual ReportMay 7, 2019Tigermed (stock code: 300347) released its annual report 2018 on April 26, 2019.According to the annual report, Tigermed maintained rapid growth in business performance in 2018. During the reporting period,...

Clinflash Releases New Version of EDC SystemNovember 8, 2018Clinflash Healthcare Technology, a subsidiary of Tigermed Group, releases the new version of Electronic Data Capture (EDC) system in Shanghai on Nov 8, 2018. Gary Guan, general manager of...

Strategic Cooperation Agreement Signed Between Tigermed and Haihe PharmaceuticalSeptember 14, 2018An agreement on long-term strategic cooperaiton was signed between Hangzhou Tigermed Consulting Co., Ltd. (“Tigermed”) and Shanghai HaiHe Biopharma Co., Ltd....

Tigermed Center Laboratory Partner Recognized by BARC Global Central LaboratorySeptember 12, 2018We are pleased to announce the long-term cooperation between Frontage Lab, Teddy Lab and BARC Global Central Lab, allowing biopharmaceuticalcompanies, Contract...